EE9900275A - CD40L-vastaste ühendite terapeutilise manustamise meetodid - Google Patents

CD40L-vastaste ühendite terapeutilise manustamise meetodid

Info

Publication number
EE9900275A
EE9900275A EEP199900275A EEP9900275A EE9900275A EE 9900275 A EE9900275 A EE 9900275A EE P199900275 A EEP199900275 A EE P199900275A EE P9900275 A EEP9900275 A EE P9900275A EE 9900275 A EE9900275 A EE 9900275A
Authority
EE
Estonia
Prior art keywords
methods
therapeutic administration
compounds against
against cd40l
cd40l
Prior art date
Application number
EEP199900275A
Other languages
English (en)
Estonian (et)
Inventor
L. Kalled Susan
W. Thomas David
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE9900275A publication Critical patent/EE9900275A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP199900275A 1997-01-10 1998-01-09 CD40L-vastaste ühendite terapeutilise manustamise meetodid EE9900275A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3467297P 1997-01-10 1997-01-10
US4015497P 1997-03-07 1997-03-07
PCT/US1998/000573 WO1998030241A1 (en) 1997-01-10 1998-01-09 Methods of therapeutic administration of anti-cd40l compounds

Publications (1)

Publication Number Publication Date
EE9900275A true EE9900275A (et) 2000-02-15

Family

ID=26711241

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900275A EE9900275A (et) 1997-01-10 1998-01-09 CD40L-vastaste ühendite terapeutilise manustamise meetodid

Country Status (20)

Country Link
US (2) US20020071840A1 (is)
EP (1) EP0966302B1 (is)
JP (1) JP2001508450A (is)
KR (2) KR100632846B1 (is)
CN (1) CN1248921A (is)
AT (1) ATE356634T1 (is)
AU (1) AU721697B2 (is)
BR (1) BR9807471A (is)
CA (1) CA2277223A1 (is)
CZ (1) CZ244399A3 (is)
DE (1) DE69837322T2 (is)
EA (1) EA001426B1 (is)
EE (1) EE9900275A (is)
IL (1) IL130785A0 (is)
IS (1) IS5101A (is)
NO (1) NO993275L (is)
NZ (1) NZ337073A (is)
PL (1) PL193966B1 (is)
TR (1) TR199902192T2 (is)
WO (1) WO1998030241A1 (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
CN1202864C (zh) * 1997-05-17 2005-05-25 拜奥根有限公司 Cd40:cd154结合阻断物在制备预防逆适应性免疫应答,特别是移植物排斥反应的药物中的用途
WO1998058672A1 (en) * 1997-06-20 1998-12-30 Biogen, Inc. Cd154 blockade therapy for therapeutic protein inhibitor syndrome
JP2002526455A (ja) * 1998-09-21 2002-08-20 ジェネティックス インスティテュート インク． 治療用たんぱく質に対する免疫応答を下方変調する方法
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
US20030170231A1 (en) * 2000-03-06 2003-09-11 Toshihiko Yamauchi Remedies and preventives for antiphospholipid antibody syndrome
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
CN100494182C (zh) 2000-05-12 2009-06-03 基酶有限公司 肿瘤坏死α因子信号的调节因子
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
AU2003291143A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
EP2367849B1 (en) 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
WO2025117849A1 (en) 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235683A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
DK0721469T3 (da) * 1993-09-02 2000-05-01 Dartmouth College Anti-gp39-antistoffer og anvendelse deraf
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
WO1995006480A1 (en) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Methods of prolonged suppression of humoral immunity
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
EP0751781B1 (en) * 1993-12-23 2004-05-26 Immunex Corporation Use of monoclonal antibodies or soluble oligomeric ligands in the manufacture of a medicament for the prevention or treatment of neoplastic disorders
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations

Also Published As

Publication number Publication date
KR20050088494A (ko) 2005-09-06
DE69837322D1 (de) 2007-04-26
ATE356634T1 (de) 2007-04-15
CA2277223A1 (en) 1998-07-16
NO993275L (no) 1999-09-09
AU721697B2 (en) 2000-07-13
AU5735398A (en) 1998-08-03
EP0966302A1 (en) 1999-12-29
NO993275D0 (no) 1999-07-01
US20020071840A1 (en) 2002-06-13
DE69837322T2 (de) 2007-11-22
JP2001508450A (ja) 2001-06-26
BR9807471A (pt) 2000-03-21
IS5101A (is) 1999-06-30
TR199902192T2 (xx) 1999-12-21
KR100632846B1 (ko) 2006-10-16
KR20000070035A (ko) 2000-11-25
CZ244399A3 (cs) 1999-10-13
HK1024424A1 (en) 2000-10-13
EA001426B1 (ru) 2001-02-26
EP0966302B1 (en) 2007-03-14
US20050158314A1 (en) 2005-07-21
PL193966B1 (pl) 2007-04-30
WO1998030241A1 (en) 1998-07-16
PL334500A1 (en) 2000-02-28
IL130785A0 (en) 2001-01-28
NZ337073A (en) 2001-01-26
EA199900633A1 (ru) 2000-02-28
CN1248921A (zh) 2000-03-29

Similar Documents

Publication Publication Date Title
EE9900275A (et) CD40L-vastaste ühendite terapeutilise manustamise meetodid
CY1118651T1 (el) Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
IS5890A (is) Aðferð til að gefa sýklalyf
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
FI961976A0 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
DK0900200T5 (da) Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet
IL192287A0 (en) Pharmaceutical compositions and methods for use
PT1039900E (pt) Agentes terapeuticos
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
DK1140103T3 (da) Ponazuril til behandling af neurologiske og abortfremkaldende sygdomme forårsaget af Coccidia
ATE248607T1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
DK1244442T3 (da) Fremgangsmåde til bestemmelse af nukleotidsynteseinhibitorer med færre bivirkninger
DK1011672T3 (da) Anvendelse af (E)-metanicotin derivater til frembringelse af analgetiske virkninger
EA200200846A1 (ru) Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона

Legal Events

Date Code Title Description
HC1A Change of owner name